Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Key Highlights
- ➤Pyxis Oncology will present MICVO Phase 1 monotherapy data in recurrent/metastatic HNSCC
- ➤MICVO received FDA Fast Track Designation for previously treated recurrent/metastatic HNSCC
- ➤Two posters will highlight MICVO mechanism and combination research in HNSCC models
- ➤MICVO is being evaluated with KEYTRUDA in a Phase 1/2 solid-tumor study
Expert Statements
Faye M. Johnson, M.D., Ph.D., The University of Texas MD Anderson Cancer Center
“Phase 1 study of micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)”
BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral presentation on micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) at the 38(th) EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Barcelona, Spain, November 18 - November 20, 2026.
In addition, Pyxis Oncology will present two posters highlighting preclinical research involving MICVO during the symposium’s antibody-drug conjugates session.
Get started
Create a free account to read the full story.